✦ LIBER ✦

Zearalenone in cereals for human nutrition: relevant data for the Swiss population

✍ Scribed by Peter Rhyn; Otmar Zoller

Publisher: Springer
Year: 2003
Tongue: English
Weight: 125 KB
Volume: 216
Category: Article
ISSN: 0044-3026
DOI: 10.1007/s00217-003-0674-7

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Genetic polymorphism of human serum tran

Genetic polymorphism of human serum transferrin in the swiss population: Evidence for three “new” transferrin-variants

✍ Rudolf Scherz; Beatrice Reber; Rolf Pflugshaupt; René Bütler 📂 Article 📅 1985 🏛 John Wiley and Sons 🌐 English ⚖ 677 KB

Population genetic and family data for t

Population genetic and family data for the human minisatellite locus D16S309 (MS205) in Germans

✍ L. Henke; S. Cleef; M. Tahar; I. Kops; J. Henke 📂 Article 📅 1996 🏛 Springer-Verlag 🌐 German ⚖ 346 KB

Elucidation of seventeen human periphera

Elucidation of seventeen human peripheral blood B-cell subsets and quantification of the tetanus response using a density-based method for the automated identification of cell populations in multidimensional flow cytometry data

✍ Yu Qian; Chungwen Wei; F. Eun-Hyung Lee; John Campbell; Jessica Halliley; Jamie 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 645 KB

Efficacy and safety of certolizumab pego

Efficacy and safety of certolizumab pegol in an unselected crohn's disease population: 26-week data of the FACTS II survey

✍ Stephan R. Vavricka; Alain M. Schoepfer; Georg Bansky; Janek Binek; Christian Fe 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 282 KB

Background: Certolizumab pegol (Cimzia, CZP) was approved for the treatment of Crohn's disease (CD) patients in 2007 in Switzerland as the first country worldwide. This prospective phase IV study aimed to evaluate the efficacy and safety of CZP over 26 weeks in a multicenter cohort of practice-based